E157 - (CME) Wide Awake: An Update on Best Practices for the Treatment and Management of Insomnia
NEI Podcast
The Importance of Timing in Sleep
Aurexin drugs have been scheduled. They very much are. And simply has, I think, a product of the basic animal studies which showed some degree of self-reinbursement in these drugs. A higher dose at bedtime would be better for people with insomnia. These are primarily on lessons to like in the case of your son who may have difficult defile.
In this episode, Dr. Andrew Cutler interviews Dr. Karl Doghramji on best practices for the treatment and management of insomnia.
Optional CME/CE Credits and Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME/CE credit, click: https://nei.global/POD22-Sleep
Learning Objectives: After completing this educational activity, you should be better able to:
- Utilize assessment tools in the diagnosis of insomnia
- Address challenges in the pharmacologic treatment of insomnia
- Implement evidence-based pharmacological treatments for insomnia
Accreditation: In support of improving patient care, Neuroscience Education Institute (NEI) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
NEI designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
A posttest score of 70% or higher is required to receive CME/CE credit. The content in this activity pertains to pharmacology and is worth 1.0 continuing education hour of pharmacotherapeutics.
Credit Types. The following are being offered for this activity:
- Nurse Practitioner: ANCC contact hours
- Pharmacy: ACPE application-based contact hours
- Physician: ACCME AMA PRA Category 1 Credits ™
- Physician Assistant: AAPA Category 1 CME credits
- Psychology: APA CE credits
- Social Work: ASWB-ACE CE credits
- Non-Physician Member of the Healthcare Team: Certificate of Participation stating the program is designated for AMA PRA Category 1 Credits ™
Peer Review: The content was peer-reviewed by an MD specializing in psychiatry to ensure the scientific accuracy and medical relevance of information presented and its independence from bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME/CE activity.
Disclosures: All individuals in a position to influence or control content were required to disclose all relevant financial relationships. Any potential conflicts of interest were identified and mitigated prior to the activity being planned, developed, or presented.
InterviewerAndrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NYChief Medical Officer, Neuroscience Education Institute, Carlsbad, CAConsultant/Advisor: AbbVie, Acadia, AiCure, Alfasigma, Alkermes, Allergan, Atentiv, Cognitive Research, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sage, Sunovion, Supernus, Takeda, Teva Speakers Bureau: AbbVie, Acadia, Alkermes, Allergan, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sunovion, Supernus, Takeda, Teva, Tris
IntervieweeKarl Doghramji, MDProfessor, Department of Psychiatry & Human Behavior; Associate Professor, Departments of Neurology and of Medicine; Medical Director, Jefferson Sleep Disorders Center; Program Director, Fellowship in Sleep Medicine; Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PAResearch/Grant: Harmony, Inspire Consultant/Advisor: Axsome, Eisai, Jazz, Harmony, Idorsia, Imbrium, Inspire Stockholder: Merck
Pre-Interview AuthorSabrina K. Bradbury-Segal, PhDMedical Writer, Neuroscience Education Institute, Carlsbad, CANo financial relationships to disclose.
The Planning Committee and Peer Reviewer have no financial relationships to disclose.
Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses.
Cultural Linguistic Competencies and Implicit Bias: A variety of resources addressing cultural and linguistic competency, and strategies for understanding and reducing implicit bias can be found in this handout.
Support: This activity is supported by an unrestricted educational grant from Eisai.
Released: August 31, 2022 CE credit expires: August 31, 2025
The AI-powered Podcast Player
